Search

Displaying results 5471 - 5480 of 10000 in total
  1. Drug

    Olvimulogene nanivacirepvec

    go.drugbank.com/drugs/DB16268
    Investigational

    Olvimulogene nanivacirepvec is under investigation in clinical trial NCT01443260 (A Study of GL-ONC1, an Oncolytic Vaccinia Virus, in Patients With Advanced Peritoneal Carcinomatosis).

  2. Drug

    IP-2018

    go.drugbank.com/drugs/DB19049
    Investigational

    IP-2018 is under investigation in clinical trial NCT04686916 (Clinical Trial Studying the Efficacy and Safety of IP2018 in Depressed, Erectile Dysfunction (ED) Patients).

  3. Drug

    GLP-1 (7-36) amide

    go.drugbank.com/drugs/DB19258
    Investigational

    GLP-1 (7-36) amide is under investigation in clinical trial NCT01185119 (Effect of GLP-1 on Glucose Metabolism in CNS Assessed by PET).

  4. Drug

    Acetylcysteine zidrimer

    go.drugbank.com/drugs/DB16496
    Investigational

    Synonyms: Dendrimer N-acetyl-cysteine
  5. Drug

    Vanoxerine

    go.drugbank.com/drugs/DB03701
    Investigational

    It was synthesized in the late 1970s and developed as a potential treatment for depression. … [A248555] Vanoxerine is an investigational drug and has not been approved for therapeutic use.

  6. Drug

    Influenza B virus B/Brisbane/60/2008 antigen (UV, formaldehyde inactivated)

    go.drugbank.com/drugs/DB10598
    ApprovedWithdrawn

    Inactivated virus cannot replicate, and therefore cannot cause disease from infection, even in immunocompromised individuals. … In contrast, live vaccines are produced from "wild-type" or disease-causing viruses that have been attenuated, or weakened, through various laboratory techniques.

  7. Drug

    Influenza B virus B/Phuket/3073/2013 antigen (UV, formaldehyde inactivated)

    go.drugbank.com/drugs/DB10599
    ApprovedWithdrawn

    Inactivated virus cannot replicate, and therefore cannot cause disease from infection, even in immunocompromised individuals. … In contrast, live vaccines are produced from "wild-type" or disease-causing viruses that have been attenuated, or weakened, through various laboratory techniques.

  8. Drug

    Influenza A virus A/South Australia/55/2014 IVR-175 (H3N2) antigen (propiolactone inactivated)

    go.drugbank.com/drugs/DB10601
    ApprovedWithdrawn

    Inactivated virus cannot replicate, and therefore cannot cause disease from infection, even in immunocompromised individuals. … In contrast, live vaccines are produced from "wild-type" or disease-causing viruses that have been attenuated, or weakened, through various laboratory techniques.

  9. Drug

    Influenza A virus A/California/7/2009 (H1N1) recombinant hemagglutinin antigen

    go.drugbank.com/drugs/DB10773
    ApprovedInvestigationalWithdrawn

    Inactivated virus cannot replicate, and therefore cannot cause disease from infection, even in immunocompromised individuals. … In contrast, live vaccines are produced from "wild-type" or disease-causing viruses that have been attenuated, or weakened, through various laboratory techniques.

  10. Drug

    Influenza A virus A/Christchurch/16/2010 NIB-74XP (H1N1) antigen (formaldehyde inactivated)

    go.drugbank.com/drugs/DB10996
    ApprovedWithdrawn

    Inactivated virus cannot replicate, and therefore cannot cause disease from infection, even in immunocompromised individuals. … In contrast, live vaccines are produced from "wild-type" or disease-causing viruses that have been attenuated, or weakened, through various laboratory techniques.